Stéphane Bancel, CEO of Moderna, the biotech making a COVID-19 vaccine - Business Insider

United States News News

Stéphane Bancel, CEO of Moderna, the biotech making a COVID-19 vaccine - Business Insider
United States Latest News,United States Headlines
  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 25 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

Meet Stéphane Bancel, the CEO of Moderna, a company developing a coronavirus vaccine in record time that is showing early signs of success in a preliminary study

Stéphane Bancel is the CEO of Moderna, a Massachusetts-based biotech company that is working on a coronavirus vaccine.Business Insider

On May 18, Moderna released results from the first human trials. These trials were focused on safety. While the results don't yet show if the vaccine would prevent people from being infected, the vaccine candidate did lead to antibody responses in healthy volunteers.Source:While vaccines typically work by giving a patient a tiny bit of the virus they're trying to kill, Moderna's coronavirus vaccine uses just the ribonucleic acid genetic material from the virus.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

BusinessInsider /  🏆 729. in US

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Moderna's COVID-19 vaccine shows early promise; shares soarModerna's COVID-19 vaccine shows early promise; shares soarEarly data from Moderna Inc's COVID-19 vaccine, the first to be tested in the United States, showed that it produced protective antibodies in a small group of healthy volunteers, the company said on Monday.
Read more »

Moderna reports positive data on early-stage coronavirus vaccine trial, shares surgeModerna reports positive data on early-stage coronavirus vaccine trial, shares surgeModerna said its early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all participants, sending its shares surging.
Read more »

Moderna reports 'positive' data on early-stage coronavirus vaccine trial, shares surge 39%Moderna reports 'positive' data on early-stage coronavirus vaccine trial, shares surge 39%Moderna's early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all 45 participants, sending the company's shares surging.
Read more »

Moderna Says Initial Covid-19 Vaccine Results Are PositiveModerna Says Initial Covid-19 Vaccine Results Are PositiveModerna said human subjects in a Phase 1 trial of a candidate Covid-19 vaccine produced immune responses that were a positive sign of the vaccine’s potential to prevent infection with the new coronavirus
Read more »

Pfizer: COVID-19 Vaccine Could Arrive in OctoberPfizer: COVID-19 Vaccine Could Arrive in OctoberPharmaceutical company Pfizer plans to expand human clinical trials for a coronavirus vaccine and include thousands of people by September, according to CNBC. What to know:
Read more »

Latest on global search for coronavirus vaccine: Oxford vaccine may protect monkeys from COVIDLatest on global search for coronavirus vaccine: Oxford vaccine may protect monkeys from COVIDA single dose of a vaccine being developed by Oxford University in England caused rhesus macaque monkeys to develop antibodies to coronavirus within 28 days.
Read more »



Render Time: 2025-02-26 19:23:32